A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: Application to inhaled bronchodilators

European Journal of Pharmaceutical Sciences

Volumn 34, Issue 4-5, 2008, Pages 250-256

  Agoram, Balaji M ^a   Milligan, Peter A ^a   van der Graaf, Piet H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Area under effect curve; Inhaled PKPD; Long acting beta agonists; NONMEM; PKPD modelling

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; COMPARATIVE STUDY; DOG; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; LUNG RESISTANCE; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; SIMULATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AIRWAY RESISTANCE; ANIMALS; BRONCHODILATOR AGENTS; COMPUTER SIMULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LUNG; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RECEPTORS, ADRENERGIC, BETA-2; REPRODUCIBILITY OF RESULTS;

EID: 47249084625     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.04.007     Document Type: Article

References (23)

1. Anderson G.P., Linden A., and Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur. Respir. J. 7 (1994) 569-578
2. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993) 457-478
3. de la Pena A., Liu P., and Derendorf H. Microdialysis in peripheral tissues. Adv. Drug Deliv. Rev. 45 (2000) 189-216
4. DeKorte C.J. Current and emerging therapies for the management of chronic inflammation in asthma. Am. J. Health. Syst. Pharm. 60 (2003) 1949-1959 quiz 1960-1
5. Derendorf H., and Hochhaus G. Dose optimization based on pharmacokinetic-pharmacodynamic modeling. In: Derendorf H., and Hochhaus G. (Eds). Handbook of pharmacokinetic/pharmacodynamic correlation (1995), CRC Press, Boca Raton 79-120
6. Disse B., Reichl R., Speck G., Traunecker W., Ludwig Rominger K.L., and Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52 (1993) 537-544
7. Disse B.G., and Ziegler H.W. Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. Respiration 51 Suppl. 1 (1987) 15-22
8. Gabrielsson J., and Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th ed. (2006), Swedish Pharmaceutical Press, Stockholm
9. Gibaldi M., Levy G., and Weintraub H. Commentary. Drug distribution and pharmacologic effects. Clin. Pharmacol. Ther. 12 (1971) 734-742
10. Jacqmin P., Snoeck E., van Schaick E.A., Gieschke R., Pillai P., Steimer J.L., and Girard P. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J. Pharmacokinet. Pharmacodyn. 34 1 (2007) 57-85
11. Jara M., Lanes S.F., Wentworth III C., May C., and Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug. Saf. 30 (2007) 1151-1160
12. Johnson M. Pharmacology of long-acting beta-agonists. Ann. Allergy Asthma Immunol. 75 (1995) 177-179
13. Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr. Respir. Rev. 2 (2001) 57-62
14. Krzyzanski W., and Jusko W.J. Characterization of pharmacodynamic recession slopes for direct and indirect response models. J. Pharmacokinet. Biopharm. 26 (1998) 409-436
15. Krzyzanski W., and Jusko W.J. Integrated functions for four basic models of indirect pharmacodynamic response. J. Pharm. Sci. 87 (1998) 67-72
16. Levy G. Pharmacokinetics of succinylcholine in newborns. Anesthesiology 32 (1970) 551-552
17. Levy G. Effect of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of mivacurium in humans. Pharm. Res. 11 (1994) 772-773
18. Marchand S., Dahyot C., Lamarche I., Mimoz O., and Couet W. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob. Agents Chemother. 49 (2005) 2356-2361
19. Matera M.G., and Cazzola M. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?. Drugs 67 (2007) 503-515
20. Pillai G., Gieschke R., Goggin T., Jacqmin P., Schimmer R.C., and Steimer J.L. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br. J. Clin. Pharmacol. 58 (2004) 618-631
21. Teschemacher A., and Lemoine H. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J. Pharmacol. Exp. Ther. 288 (1999) 1084-1092
22. Traunecker W., and Muacevic G. Pharmacological effects of a combination of fenoterol hydrobromide and ipratropium bromide. Respiration 50 (1986) 244-251
23. Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A., and Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J. Pharmacol. Exp. Ther. 319 (2006) 682-692